Inspire Medical Systems (NYSE:INSP – Get Free Report) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.
A number of other equities research analysts also recently issued reports on the stock. Weiss Ratings downgraded shares of Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. Robert W. Baird cut their price target on Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating for the company in a report on Tuesday, May 5th. Bank of America downgraded shares of Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price objective on the stock. in a research note on Friday, May 22nd. Royal Bank Of Canada cut shares of Inspire Medical Systems from a “sector perform” rating to a “buy” rating in a research note on Monday, June 15th. Finally, Truist Financial reduced their price target on shares of Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating for the company in a report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Inspire Medical Systems has a consensus rating of “Hold” and an average target price of $81.05.
View Our Latest Analysis on Inspire Medical Systems
Inspire Medical Systems Trading Up 1.4%
Inspire Medical Systems (NYSE:INSP – Get Free Report) last issued its earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. The firm had revenue of $204.58 million during the quarter, compared to analysts’ expectations of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same period last year, the firm posted $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, research analysts forecast that Inspire Medical Systems will post 0.93 earnings per share for the current year.
Hedge Funds Weigh In On Inspire Medical Systems
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Daiwa Securities Group Inc. grew its holdings in shares of Inspire Medical Systems by 38.7% during the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after purchasing an additional 130 shares during the last quarter. State of Wyoming raised its holdings in shares of Inspire Medical Systems by 31.5% in the fourth quarter. State of Wyoming now owns 731 shares of the company’s stock valued at $67,000 after buying an additional 175 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after buying an additional 205 shares in the last quarter. Apollon Wealth Management LLC grew its holdings in Inspire Medical Systems by 5.6% during the 1st quarter. Apollon Wealth Management LLC now owns 3,997 shares of the company’s stock worth $206,000 after acquiring an additional 212 shares during the last quarter. Finally, Blair William & Co. IL increased its position in Inspire Medical Systems by 5.1% in the 3rd quarter. Blair William & Co. IL now owns 4,865 shares of the company’s stock valued at $361,000 after acquiring an additional 234 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.
About Inspire Medical Systems
Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.
The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.
Featured Articles
- Five stocks we like better than Inspire Medical Systems
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
